Hepatitis

Unitaid Board supports integrated approach to fighting leading causes of HIV deaths

WHO commends UNITAID for new investment in advanced HIV disease, hepatitis

13 June 2017 - The World Health Organization (WHO) welcomes UNITAID’s announcement of new investment in more integrated care to improve the health of people living with HIV, hepatitis and human papillomavirus (HPV). The UNITAID Board announced that the organization has expanded its investments to fund projects to increase treatment access for people with advanced HIV disease, coinfected with viral hepatitis, or cervical cancer.

Unitaid/G.Donini
Pills

New WHO essential medicines' list includes treatments for HIV and hepatitis

9 June 2017 - WHO released updated essential medicines list for 2017. The list advises countries on which antibiotics to use for common infections and which to preserve for the most serious circumstances, with the aim of fighting antimicrobial resistance. The list also included new medicines to treat all six types of hepatitis C infection, improved HIV treatment, and pre-exposure prophylaxis with tenofovir alone, or in combination with emtricitabine or lamivudine, to prevent HIV infection.

WHO
Dr H.A.R. Al Rand, United Arab Emirates; Professor Lô Boubou Baïdy (Mauritania), Winner of the 2017 United Arab Emirates Health Foundation Prize; His Excellency, Ambassador Obaid Salem Saeed Al Zaabi, Permanent Representative of the United Arab Emirates to the United Nations Office; Mr Yohei Sasakawa, WHO Goodwill Ambassador for Leprosy Elimination and Chairman of the Nippon Foundation; Ms Ayush Tsogtsetseg, Minister of Health of Mongolia representing Dr Arslan Rinchin, winner of the 2017 Sasakawa Health Prize; Dr Veronika Skvortsova, Minister of Healthcare of the Russian Federation and president of the Seventieth World Health Assembly; Dr Margaret Chan, WHO  Director-General; Dr Etsuko Kita;  Mr Yo han IHN, President of the Korea Foundation for International Health Care; H.E. Dr.Roberto Morales Ojeda, Minister of Health of Cuba; Dr Felix Baez Sarria, Henry Reeve International Medical Brigade and winner of the 2017 Dr LEE Jong-wook Memorial Prize for Public Health

Health professionals awarded for efforts in viral hepatitis

26 May 2017 – At the Seventieth World Health Assembly, health professionals from Mauritania and Mongolia were awarded prestigious public health prizes for their lifelong dedication and efforts in developing primary health care in their countries and reducing the burden of viral hepatitis. Dr Rinchin Arslan of Mongolia was awarded the 2017 Sasakawa Health Prize, and Professor Lô Boubou Baïdy of Mauritania, the United Arab Emirates Health Foundation Prize.

WHO/L. Cipriani
New goodwill ambassador for hepatitis in WHO South-East Asia Region

New Goodwill Ambassador for hepatitis in WHO South-East Asia Region

12 May 2017 – Legendary Indian actor Mr Amitabh Bachchan was appointed today as a Goodwill Ambassador for hepatitis in the WHO South-East Asia Region. In accepting the appointment, Mr Bachchan said, "I am absolutely committed to the cause of hepatitis. As a person living with hepatitis B, I know the pain and sufferings that hepatitis causes. No one should ever suffer from viral hepatitis." Dr Gottfried Hirnschall, WHO Director for HIV and hepatitis, said "Mr Amitabh Bachchan's courage, commitment and compassion are widely appreciated by the global hepatitis community. We need champions like Mr Bachchan to speak out on viral hepatitis to influence opinion leaders and to accelerate the hepatitis response."

WHO
Mother with a child, Ayacucho, Peru (hepatitis B).

WHO Director-General hails progress in HIV and hepatitis

9 May 2017 –WHO Director-General, Dr Margaret Chan has highlighted dramatic transformations in the global fight against HIV/AIDS, and rapid visibility gained in the emerging response to viral hepatitis, in her final report Ten years in public health 2007–2017. In the chapter, Viral hepatitis: a hidden killer gains visibility, Dr Chan highlights the WHO's rapid response to viral hepatitis, and the global support and commitments required to make its elimination a reality. “Many hard-won lessons from the HIV experience provided a head start for aggressive action against viral hepatitis, which is becoming a leading killer," states Dr Chan. "WHO acted quickly to fight the stigma attached to a disease prevalent in marginalized communities, issuing a viral hepatitis strategy in 2016, followed in 2017 by a report that gives countries guidance on implementation of the strategy.”

PAHO
WHO Global Hepatitis Report, 2017 - Infographic

WHO launches its first Global hepatitis report

21 April 2017 – The World Health Organization releases a first Global hepatitis report with global and regional estimates on viral hepatitis B and C burden, mortality and incidence. The new report reveals that a large majority of an estimated 325 million people living with the disease lacks access to life-saving testing and treatment. As a result, millions of people are at risk of a slow progression to chronic liver disease, cancer and death.

WHO
Participants at the first World Hepatitis Summit, 2015

World Hepatitis Summit 2017 – Programme launched

The programme for the World Hepatitis Summit 2017 has now been launched. The theme of this year’s Summit is Implementing the Global Health Sector Strategy on Viral Hepatitis (GHSS): Towards the elimination of hepatitis as a public health threat. This programme seeks to promote advocacy, encourage the exchange of ideas and facilitate learning to use in the fight against viral hepatitis. It has been created by a Programme Secretariat and sub-Committees made up of experts in the field of hepatitis and civil society groups. Additional content and speakers will continue to be added over the next few months.

World Hepatitis Alliance

fact buffet

Global burden

325 millionEstimated 325 million people were living with chronic hepatitis infections (HBV or HCV) worldwide in 2015.

For more: fact sheet on hepatitis B

Silent killer

1.34 millionGlobally, 1.34 million people died of viral in 2015.

For more: global strategy on viral hepatitis

Effective treatment

>95% Over 95% of people with hepatitis C can be completely cured within 2-3 months.

For more: fact sheet on hepatitis C




World Hepatitis Day 2017

World Hepatitis Summit

World Hepatitis Summit 2017

Date: 1-3 November 2017 Place: São Paulo, Brazil

Global strategy

Global health sector strategy on viral hepatitis 2016-2021

Global health sector strategy on viral hepatitis 2016-2021


#Hepatitis

Stay connected

Global Hepatitis Programme